#### ![calendar-Icon](/themes/custom/cosmos/patterns/images/calendar-v2.svg)June 02, 2024

 

 #### Chicago, USA

 

 

 

[Download the presentation (PDF 1.0 MB)](/sites/novartis_com/files/2024-novartis-asco-investor-event-presentation.pdf "2024-novartis-asco-investor-event-presentation.pdf")

[Read the press release: Novartis Scemblix® Phase III data first to show superior efficacy with a favorable safety and tolerability profile vs. standard-of-care TKIs in adults with newly diagnosed CML](/news/media-releases/novartis-scemblix-phase-iii-data-first-show-superior-efficacy-favorable-safety-and-tolerability-profile-vs-standard-care-tkis-adults-newly-diagnosed-cml "Novartis Scemblix® Phase III data first to show superior efficacy with a favorable safety and tolerability profile vs. standard-of-care TKIs in adults with newly diagnosed CML ")